The Latest Breaking News from Eli Lilly

The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.

A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1 drugs, and amylin-based drugs are next. Novo Nordisk's compound, Cagrilintide, will be combined with semaglutide in its…

Eli Lilly is taking the HRSA to court for allegedly blocking the pharma's discount plan.

US pharmaceuticals group Eli Lilly is to conduct trials of its weight-loss drugs in the UK.

For Eli Lilly CEO Dave Ricks, speeding up the drug discovery process is essential to success.

Eli Lilly has outperformed the broader market and its peers this year, and Wall Street analysts are bullish about the stock’s prospects.

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

December Nasdaq 100 E-Mini futures (NQZ24) are trending up +0.28% this morning as strong quarterly results from Alphabet boosted sentiment, while investors also awaited a fresh batch of U.S. economic data and earnings reports from “Magnificent Seven” companies Microsoft and Meta.

As drugs emerge as vital to the Government’s anti-obesity strategy, BBC Panorama is shedding light on the pharmaceuticals industry behind them

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Eli Lilly has filed three new separate lawsuits accusing vendors and a medical spa of selling knock-off versions of their drug, Zepbound.